Ondansetron

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 21.12.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

5-HT3 antagonist, antiemetic.

Pharmacodynamics (Effect)This section has been translated automatically.

Selective, competitive binding to 5-HT3 receptors in the brain and elsewhere. As a result, serotonin can no longer bind to its binding sites on the 5-HT3 receptors and develop its effect. This directly prevents the development of nausea and vomiting, for example.

IndicationThis section has been translated automatically.

Cytostatic-induced vomiting, nephrogenic pruritus.

Limited indicationThis section has been translated automatically.

Pregnancy, lactation, intestinal stenosis, liver dysfunction.

Pregnancy/nursing periodThis section has been translated automatically.

Do not use during pregnancy (insufficient data available). Do not use while breastfeeding or discontinue breastfeeding before starting therapy, as the preparation passes into breast milk.

Dosage and method of useThis section has been translated automatically.

Chemotherapy: 8 mg slowly i.v. or as a short infusion 15 min. before administration of the chemotherapeutic agent, then continuous infusion of 1 mg/hour over 24 hrs. or 8 mg p.o. 3 times/day.

Nephrogenic pruritus: 2-3 times/day 8 mg p.o.

Children > 2 yrs: Immediately before chemotherapy 5 mg/m2KO slowly i.v. over 15 minutes. Followed by oral administration of 4 mg every 12 hours (morning and evening) for 5 days.

Undesirable effectsThis section has been translated automatically.

Cutaneous adverse reactions: Rare hypersensitivity reactions, occasionally anaphylactoid reactions. Mild exanthematous skin lesions. Local reactions at the infusion site. In urticaria patients, application of the active substance may induce an episode.

Extracutaneous UAWs: Minor to moderate headache, constipation of mild or moderate severity, eye dryness. Occasionally flu-like symptoms with fever and chills.

ContraindicationThis section has been translated automatically.

Children < 2 years, hypersensitivity reactions to other 5-HT3 antagonists.

PreparationsThis section has been translated automatically.

Zofran

Authors

Last updated on: 21.12.2020